Funding
Micrin-relevant areas of unmet medical need
- BPH/Prostate Cancer
- Breast Cancer
- Heart Failure
- Endometriosis
- PCOS
- Acromegaly
- Infertility
The potential for micrin-related medicaments to make a contribution to reducing human suffering is significant. In pursuit of this potential the company has spent about £3.0m in its 12-year history. This has mainly consisted of investment funding, but includes grants from the UK government in the form of SMART Feasibility and Development Awards, received after rigorous third-party due diligence reviews.
New funds are being sought exclusively from private sources to extend the micrin patent portfolio and to enable the company to outlicense its technology to pharmaceutical and biotech industry partners.
The aim of outlicensing is to achieve cash self-sufficiency, enabling the return of monies to shareholders as expediently as possible. Endocrine’s aim is to do well by its shareholders, by doing good in the world.
Disclaimer: The above statements do not constitute an offer or invitation to the public to subscribe for or purchase any equity share capital of any company.